Tests modified immune cells against B cell cancers in people with CD19 or CD22
Tests CAR-T cells that target CD19 and CD22 in people with B cell cancers.
Plain-language title generated from the registry record
Registry title: CD19/22 Bi-specific CAR-T Cell Therapy
Key facts
- Where
- Shenzhen, ChinaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with a B cell cancer whose cancer cells carry the CD19 or CD22 marker. It tests CAR-T cell therapy aimed at both markers.
- Age
- From 6 months to 75 years.
- Sex
- All sexes can join.
- Disease stage
- A B cell malignancy (B cell cancer). Performance status (KPS score) over 80 points and expected survival of more than 1 month.
- Earlier treatment
- People who had earlier CD19 and CD22 CAR-T treatment that failed cannot join. No systemic steroid treatment within a week of the treatment.
- Biomarker or test result
- The malignant B cells must show CD19 or CD22 on their surface.
Main reasons for not taking part
- Other active diseases that make it hard to judge the response to treatment
- Bacterial, fungal or viral infection that cannot be controlled
- Living with HIV
- Active HBV or HCV infection
- Pregnant or nursing mothers
Read by machine on 9 November 2026.
Where in China
- Shenzhen Geno-immune Medical InstituteShenzhen, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shenzhen Geno-Immune Medical Institute
- Trial code
- NCT05432882
- Record updated
- 2 November 2026
- Original description
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.Read full original descriptionShow less
CD19/22 Bi-specific CAR-T Cells Targeting B Cell Malignancies
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
Inclusion: age older than 6 months; malignant B cell surface expression of CD19 or CD22 molecules; the KPS score over 80 points, and survival time is more than 1 month; greater than Hgb 80 g/L.5. no contraindications to blood cell collection.
Exclusion: pregnant and nursing mothers. 6. under systemic steroid treatment within a week of the treatment. 7. prior failed CD19 and CD22 CAR-T treatment; accompanied with other active diseases and difficult to assess patient response; bacterial, fungal, or viral infection, unable to control; living with HIV.4. active HBV or HCV infection.